SGLT2 in­hibitors nod

Pharmacy Daily - - Front page -

LAND­MARK re­search that re­vealed the car­dio­vas­cu­lar ben­e­fits of em­pagliflozin2 (Jar­diance by Boehringer In­gel­heim) in peo­ple with type 2 di­a­betes and es­tab­lished car­dio­vas­cu­lar disease has re­sulted in new guide­lines rec­om­mend­ing the prod­uct class.

Sodium glu­cose co­trans­porter 2 (SGLT2) class of medicines, which in­hibit re­ab­sorp­tion of glu­cose in the kid­ney, now have a spe­cific role de­scribed in new guide­lines by the Na­tional Heart Foun­da­tion of Aus­tralia and the Car­diac So­ci­ety of Aus­tralia and New Zealand.

CLICK HERE for the guide­lines.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.